Multiple reports describe a new class of medicines aimed at reducing hot flushes and night sweats, symptoms commonly experienced during menopause. The coverage highlights early work led by Waljit Dhillo, a professor of endocrinology and metabolism, who has been associated with initial trials of these drugs. Dhillo characterizes the effect as rapid, describing symptom relief as beginning like “turning on a switch,” with flushes easing within a day or two.
The reports also frame these medicines as a potential alternative to hormone replacement therapy (HRT), focusing on the goal of avoiding HRT-related side effects. The articles present the drugs’ mechanism and performance primarily through early trial commentary rather than detailed study results, and they do not specify all study parameters in the provided text.
Overall, the accounts agree that the drugs are intended to quickly lessen vasomotor symptoms and are being positioned as non-hormonal options that may reduce side-effect concerns compared with HRT, based on reported observations from early clinical work.
